Research programme: pleuromutilins - Nabriva Therapeutics

Drug Profile

Research programme: pleuromutilins - Nabriva Therapeutics

Alternative Names: BC-7634; BC-9074; BC-9529; BC-9563; ESP - Nabriva; Extended spectrum pleuromutilins - Nabriva

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nabriva Therapeutics
  • Class Antibacterials
  • Mechanism of Action Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Austria (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Austria (PO)
  • 24 Apr 2015 Antimicrobial data from a preclinical trial in Bacterial infections released by Nabriva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top